What’s next for Pfizer’s vaccines unit?

“We are an important growth engine for the company and there are lots of ways to grow. We will continue to grow with our current portfolio–much of which is new anyway–but if we have external opportunities that would be great,” Pfizer Vaccines President Susan Silbermann said in a recent interview.

article in FierceVaccines

Study investigates the efficacy of immunization with Pfizer’s Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) to prevent a first episode of vaccine-type pneumococcal community-acquired pneumonia … more

European Commission approves an expanded indication for the use of Prevenar 13 for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older … more

Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend Pfizer’s serogroup B meningococcal vaccination to help protect individuals at increased risk … more